Global pharma major Lupin Limited (Lupin) today announced the launch of Rivaroxaban for Oral Suspension, 1 mg/mL, in the United States. Rivaroxaban for Oral Suspension, 1 mg/mL is bioequivalent to Xarelto® for Oral Suspension, 1 mg/mL of Janssen
Pharmaceuticals, Inc. Rivaroxaban for Oral Suspension is indicated for:-
- Treatment of venous thromboembolism (VTE) and reduction in the risk of recurrent VTE in pediatric
patients from birth to less than 18 years after at least 5 days of initial parenteral anticoagulant
treatment. - Treatment of thromboprophylaxis in pediatric patients 2 years and older with congenital heart
disease after the Fontan procedure.
Rivaroxaban for Oral Suspension, 1 mg/mL (RLD Xarelto®) had estimated annual sales of USD 11
million in the U.S. (IQVIA MAT July 2025).
 today announced the launch of Rivaroxaban for Oral Suspension, 1 mg/mL, in the United States.){kind=link}